Kuur Therapeutics, founded in 2005, is dedicated to revolutionizing cancer treatment through the development of off-the-shelf engineered CAR-NKT cell therapies. The company's innovative approach involves harnessing the unique natural biology of natural killer T cells (NKT cells) and employing advanced chimeric antigen receptor (CAR) construct engineering to target both hematological and solid tumors. Kuur's groundbreaking platform has attracted attention, with a recent Secondary Market investment on 18 January 2021. This funding signifies growing confidence in Kuur's potential to deliver impactful therapies. As a biotechnology and healthcare-focused endeavor, Kuur Therapeutics is poised to make significant strides in addressing the unmet needs of cancer patients.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Secondary Market | Unknown | - | 18 Jan 2021 | |
| Series C | Unknown | - | 15 Mar 2017 | |
| Series B | Unknown | - | 25 Nov 2014 | |
| Venture - Series Unknown | Unknown | - | 23 Jul 2012 | |
| Grant | Unknown | - | 31 Dec 2009 |
No recent news or press coverage available for Kuur Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
